Relationship between calcium channel blocker class and mortality in dialysis

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• The comparative effectiveness of dihydropyridine (DHP) and non-DHP calcium channel blockers (CCBs) in patients undergoing maintenance dialysis is not well-established.
• Hypertension is a common comorbidity in dialysis patients, necessitating effective management strategies.

Purpose of the Study:

• To compare the effectiveness of DHP versus non-DHP CCBs in reducing mortality and cardiovascular morbidity in patients on maintenance dialysis.
• To evaluate the association between different classes of CCBs and clinical outcomes in a dialysis population.

Main Methods:

• A retrospective cohort study of hypertensive patients initiating dialysis was conducted.
• New CCB initiators were identified and followed from medication exposure until an event (all-cause mortality or cardiovascular morbidity/mortality).
• Cox proportional hazards models were used to calculate adjusted hazard ratios (AHRs) comparing DHP and non-DHP CCB use.

Main Results:

• DHP use, compared to non-DHP use, was associated with a significantly reduced hazard of all-cause mortality (AHR 0.77; 99% CI, 0.64 - 0.93) and cardiovascular morbidity/mortality (AHR 0.86; 99% CI, 0.72 - 1.02).
• These findings remained consistent after including all therapy initiators and after excluding individuals with chronic atrial fibrillation.
• Sensitivity analyses confirmed the association of DHP CCBs with lower risks for both all-cause mortality and cardiovascular outcomes.

Conclusions:

• Dihydropyridine CCBs are associated with a reduced hazard of death and cardiovascular morbidity/mortality compared to non-DHP CCBs in maintenance dialysis patients.
• The findings suggest a potential benefit of DHPs in this high-risk population.
• Further investigation into the underlying mechanisms of action is warranted to elucidate these observed differences.